Autoimmune hepatitis and viral hepatitis B are different conditions, but they overlap in a way that matters: people with autoimmune disease who need immune-suppressing drugs can trigger hepatitis B reactivation if the virus is hiding in their liver. Anyone starting immunosuppression should be screened for hepatitis B first.
At a glance
- Not exposed, no immunity
- Vaccine series
- Most effective and works best before immunosuppression starts
- Starting immune-suppressing drugs
- Full HBV panel first; antiviral if positive
- Prevents reactivation of dormant virus
- Recent exposure to infected source
- HBIG + vaccine within 24 hours
- Blocks the virus from establishing infection
- Already chronic
- Specialist care, lifelong antiviral if indicated
- Suppresses virus and lowers liver-cancer risk
| Item | Value |
|---|---|
| Not exposed, no immunity | Vaccine series: Most effective and works best before immunosuppression starts |
| Starting immune-suppressing drugs | Full HBV panel first; antiviral if positive: Prevents reactivation of dormant virus |
| Recent exposure to infected source | HBIG + vaccine within 24 hours: Blocks the virus from establishing infection |
| Already chronic | Specialist care, lifelong antiviral if indicated: Suppresses virus and lowers liver-cancer risk |
This page focuses on hepatitis B (HBV), the vaccine-preventable, blood-borne and sexually transmitted liver infection, and how it intersects with autoimmune disease and the medicines used to treat it. If you have lupus, rheumatoid arthritis, inflammatory bowel disease, or any condition managed with steroids, biologics, or chemotherapy, the connection to hepatitis B is one your clinician should already be checking for.
What hepatitis B is, and why autoimmune disease matters
Hepatitis B is a liver infection caused by the hepatitis B virus CDC. Doctors split it into two phases. Acute hepatitis B is the short-term illness in the first six months after exposure; most healthy adults clear it. Chronic hepatitis B lasts beyond six months and can be lifelong. The virus is mainly spread through blood and sexual contact.
Now the autoimmune link. Your immune system normally keeps hepatitis B in check, even after you've cleared an old infection, since the virus can sit dormant in liver cells for years. When an autoimmune disease is treated with drugs that deliberately dampen the immune response, corticosteroids, rituximab and other biologics, methotrexate, or cancer chemotherapy, that brake comes off. The dormant virus can replicate again and inflame the liver, sometimes severely. This is called hepatitis b reactivation, and it's the main reason a person with autoimmune disease needs to know their hepatitis B status before treatment starts.
Reactivation can happen even in someone who tested as "recovered", meaning they cleared a past infection, because immunity from natural infection isn't the same as eradication. The screening panel checks for more than just active virus for this reason.
Symptoms, and the silent reality
Most people feel nothing. Roughly half to seventy percent of people with acute hepatitis B have no symptoms at all, and more than half of all people living with hepatitis B don't know they're infected. Chronic infection is usually silent for years.
When acute symptoms do appear, they can include fatigue, fever, poor appetite, nausea, abdominal pain, joint pain, dark urine, clay-colored stools, and jaundice (yellowing of the skin and eyes, a sign the liver is struggling to clear bilirubin). In the setting of immunosuppression, a reactivation flare can show up as a sudden rise in liver enzymes on routine bloodwork, often before the person feels sick at all. Monitoring relies on lab tests rather than waiting for symptoms.
How hepatitis B spreads
Hepatitis B spreads when blood, semen, or other body fluids from an infected person enter someone who isn't infected. The main routes are sex, sharing needles or injection equipment, and from a pregnant person to the baby at birth. It is not spread by sneezing, coughing, hugging, sharing utensils, or through food and water.
Symptoms, when they come, average about 90 days after exposure, with a range of roughly 60 to 150 days. If you've had a possible exposure, that long window is why timing your test matters, see our guide on when to test after exposure.
How it's tested
Hepatitis B is diagnosed with a triple serologic blood panel CDC:
- HBsAg (hepatitis B surface antigen): a positive result means active infection, acute or chronic.
- Anti-HBs (surface antibody): signals immunity, either from vaccination or from clearing a past infection.
- Total anti-HBc (core antibody), marks past or current infection; this is the marker that flags someone at risk for reactivation even when HBsAg is negative.
The CDC recommends every adult aged 18 and older be screened at least once in their lifetime, and pregnant people in each pregnancy CDC, 2023. For anyone with autoimmune disease facing immunosuppressive therapy, all three markers, not just HBsAg, should be checked before the first dose, because the core antibody is what identifies hidden infection.
Testing is a blood draw, results are usually back in a few days, and it's free or low-cost at health departments, Planned Parenthood, and Title X clinics. You can also order a panel and get tested without a clinic visit, or compare testing providers first.
Treatment
Acute hepatitis B usually needs only supportive care, rest, fluids, and monitoring, while a healthy immune system clears it. Chronic hepatitis B has no cure, but FDA-approved antiviral medicines suppress the virus and protect the liver, and care is managed by a liver or infectious-disease specialist CDC.
The mainstay drugs are nucleos(t)ide analogues with a high barrier to resistance, tenofovir (TDF or TAF) and entecavir, listed as preferred first-line therapy by major guidelines AASLD, 2018. Entecavir's resistance rate is only about one percent over five years in people who haven't been treated before NCBI/PMC review of entecavir, so these agents are favored over older drugs like lamivudine. Most people take these pills for life, and clearance happens in only about two to five percent even after a decade.
For the autoimmune patient, treatment is often preventive. If you carry the virus and are about to start immunosuppression, your team may put you on an antiviral as prophylaxis, started before or alongside the immune-suppressing drug and continued for a period after it stops, to keep reactivation from happening. Don't stop these pills on your own; abrupt discontinuation can itself trigger a flare.
Complications if untreated
Untreated chronic hepatitis B can cause progressive liver scarring (fibrosis), cirrhosis (severe scarring that stops the liver working properly), liver cancer, and death. Reactivation in an immunosuppressed person can be especially aggressive, sometimes causing acute liver failure, because the virus surges while the body's defenses are deliberately turned down.
The global toll is large: hepatitis B and C together caused an estimated 1.3 million deaths in 2022, and 83% of those were from hepatitis B WHO, 2024. Yet in 2022 only about 13% of people with hepatitis B were diagnosed and just under 3% were on treatment WHO, 2024. Catching the infection early is meant to close that gap.
Prevention
Vaccination is the best prevention, and it works regardless of autoimmune status. ACIP now recommends the hepatitis b vaccine for adults universally for everyone aged 19–59, and for adults 60 and older with risk factors MMWR Updated Hepatitis B. If you have an autoimmune condition and aren't immune, getting the full hepatitis b vaccine series before starting heavy immunosuppression gives the best chance of a strong antibody response, since immune-suppressing drugs can blunt how well a vaccine takes.
Other layers help too: condoms used every time lower sexual transmission, not sharing needles or razors removes a blood route, and routine screening catches the silent infections. After a known exposure to an HBsAg-positive source, post-exposure prophylaxis is hepatitis B immune globulin (HBIG) plus the vaccine, given as soon as possible, ideally within 24 hours.
| Situation | Best prevention step | Why it matters here |
|---|---|---|
| Not yet exposed, no immunity | Hepatitis B vaccine series | Most effective and works best before immunosuppression starts |
| Autoimmune disease, starting immune-suppressing drugs | Full HBV panel first; antiviral prophylaxis if positive | Prevents reactivation of dormant virus |
| Recent exposure to infected source | HBIG + vaccine within 24 hours | Blocks the virus from establishing infection |
| Already chronic | Specialist care, lifelong antiviral if indicated | Suppresses virus and lowers liver-cancer risk |
When to see a clinician
See a clinician before you start any immunosuppressive or biologic therapy for an autoimmune condition. Screen for hepatitis B then, not after. Also get checked if you have jaundice, persistent fatigue with abdominal pain, dark urine, or if routine bloodwork shows rising liver enzymes while you're on immune-suppressing medication. And if you've never been screened, the recommendation is at least once in your lifetime regardless of how you feel.
A diagnosis here is manageable, and clinics handle it every day. Knowing your status before your immune system gets turned down changes outcomes most.
Keep exploring on EasySTD: which STD test you need, STD vaccines and Hepatitis A testing.